There had been only a few complete human genomes sequenced at that point. The company's founders strongly believed that researchers needed to be able to sequence large numbers of genomes -as many as one million or more -to identify the pathways responsible for complex diseases and revolutionize medical research. There are currently more than 3000 inherited diseases for which the genetic variants responsible are unknown. Complete Genomics anticipates that large-scale human genome sequencing studies will permit the medical community to more accurately characterize diseases (e.g., describing a cancer based on the pathways involved rather than the site of the primary tumor) and to develop more targeted drugs and diagnostics to help improve health outcomes.
Complete Genomics is a life sciences company that focuses solely on complete human genome sequencing. It became a publicly listed company on the NASDAQ stock exchange on 11 November 2010, and now trades under the ticker symbol 'GNOM'. As of 30 September 2010, it had 167 employees.
Complete Genomics' platform for complete human genome sequencing is comprised of three elements -biochemistry, instrumentation and software -and it has made, and continues to make, proprietary developments in each area.
Biochemistry
Complete Genomics has developed patterned DNA arrays, known as DNA nanoballs or DNB™ arrays, which enable it to perform DNA sequencing very efficiently and thus minimize reagent and imaging costs. It begins by fragmenting the DNA into pieces, each approximately 500 bases in length, which is the optimal size for sequencing human genomes. It then amplifies those fragments into DNBs that are approximately 200 nm in diameter, which is smaller than the wavelength of light. The company is able to make billions of these DNBs in a single test tube at very low costs.
Complete Genomics has a semiconductor fabri cator to manufacture 8-inch circular wafers and then cut them into 1 × 3-inch silicon chips. A regular pattern of sticky spots is then added to each chip. Once DNBs are applied to the grid, a single DNB sticks to each of the approximately three billion spots on the chip, producing a very densely packed DNA array. Packing the DNA as tightly as possible in this manner offers two major advantages: it reduces the volume of reagents required and maximizes the efficiency of the imaging system. By ensuring that the grid of DNA spots lines up precisely with the pixels in the camera, this approach ensures that no pixels are wasted. It takes only two pixels to image a DNB.
As its sequence detection technology, Complete Genomics employs unchained ligase reads to determine which of the four bases (A, G, C or T) is present is each position. Ligase is a highly accurate, naturally occurring enzyme that provides a significant advantage in reducing potential errors in reading the order of the bases.
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Technologies that use chained reads instead have to successfully read the first base before they can read the second one, and so on. Therefore, their error rate goes up with each read. By contrast, Complete Genomics' unchained technique allows it to read bases in any order. It simply reads one base, washes off the fluorescent molecules, and then reads another one. The company then uses its proprietary software to assemble all the reads from each fragment into a complete human genome sequence.
In addition, Complete Genomics is developing a long fragment read (LFR) technology, which enables it to analyze 100,000 base s egments and thus achieve an even higher level of accuracy. It also permits the chromosomes to be sequenced independently of each other. This functions as an error correction technology and also allows researchers to determine whether specific mutations are carried on the maternal DNA, the paternal DNA or split between the two. While the ability to separate chromosomes is rarely necessary from a research perspective, it is vitally important from a clinical standpoint as it can produce different health outcomes. The company is able to conduct this test using very small samples, in some cases less than 50 cells, a critical capability for oncology applications.
Instrumentation
As Complete Genomics sequences only complete human genomes and does so at its genomesequencing factory located at the company's headquarters, it has been able to highly utilize factory automation processes. This includes an open architecture for its sequencers, enabling them to be deployed rapidly and upgraded easily. Its genome center currently has 16 sequencing instruments that operate 24 h a day, 7 days a week, and produce approximately one trillion raw base reads per day. This high-throughput facility sequenced and analyzed more than 300 complete human genomes in the third quarter of the 2010 fiscal year. Furthermore, the company will be able to deliver 400 genomes per month by the end of the year, when each instrument is expected to be sequencing one genome per day.
Software
Data analysis is perhaps the most valuable aspect of the service, providing customers with research-ready data that they can employ immediately for discovery research. The company has developed its own proprietary assembly, variant and annotation software, and has recently introduced a suite of analytical software tools, CGA Tools™, which customers use to explore their variant data further.
Research breakthroughs
Complete Genomics demonstrated proof-of-concept for its sequencing service by publishing data from its first human genome at the Advances in Genome Biology and Technology Annual Meeting on 5 February 2009. That demonstration was followed by a paper published in Science in January 2010 showing that the company had sequenced three human genomes with the high accuracy (99.999%) required by researchers [1] . Now the company's customers are publishing papers based on sequencing work that it has conducted. Genentech used Complete Genomics' service to provide a detailed picture of the genetic mutations in a primary non-smallcell lung tumor. By comparing the patient's tumor and normal genomes, researchers discovered 50,000 mutations, which was many more than observed in previous studies, and equated to approximately one mutation for every three cigarettes that the individual had smoked [2] . The Institute for Systems Biology (ISB; WA, USA) sequenced a family quartet with Complete Genomics in which both children suffered from Miller syndrome, which results in skeletal malformations, but both parents were unaffected. By sequencing these four genomes, ISB was able to identify the causal variant [3] . The University of Texas Southwestern Medical Center (TX, USA) used Complete Genomics' service to solve a difficult clinical case in which an 11-monthold patient presented with a very high cholesterol level (LDL-C of 837). Although there is a standard blood test and associated treatment for this condition, the test failed, reporting that the infant was not lacking the required protein.
Sequencing revealed that, in fact, the protein must be absent [4] . The infant was successfully treated using the recognized therapy and the source of the test error was identified as a protein in the mother's blood that was passed on through breast milk. 
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Genomics is now sequencing 100 genomes (50 tumor-normal pairs) for a National Cancer Institute pediatric cancer study as part of its Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative. The goal of this project is to identify and validate somatic mutations found in 50 pediatric cancer cases. Upon successful completion of this project, the contract contains an option to have the company sequence 1000 additional pediatric cancer genomes over 18 months.
Future perspective
As the cost of complete human genome sequencing continues to decrease (the cost to sequence the first human genome was approximately $3 billion and the current cost is approximately $10,000), this technology will transition from playing a research and discovery role into a develop mental one. As the number of human genomes sequenced moves into thousands and tens of thousands, medical researchers will identify the mechanisms responsible for specific diseases and will begin to apply that knowledge to identify biomarkers and create more targeted diagnostics and treatments.
In addition, complete human genome sequencing has the potential to identify subsets of patients who are likely to react particularly well or poorly to a medication before they receive it. This would allow physicians to prescribe a drug only to those patients who would benefit from it. This ability to stratify patients could permit drugs to be rescued that were either removed from the market or never approved owing to an adverse event in a subset of patients.
As the medical research community learns more about the genetic underpinnings of complex diseases, the inherent value in conducting complete genome screening of the population at large will increase incrementally. Complete Genomics anticipates that complete human genome sequencing will become one of the cornerstones of personalized medicine and be one of most important medical tools of the 21st Century. Ultimately, having one's genome sequenced will become as routine as getting a blood test. 
Executive summary
n Complete Genomics Inc. offers complete human genome sequencing as an outsourced service, delivering research-ready data for biological discovery.
n The company's CGA™ Platform employs proprietary biochemistry, instrumentation and software. n Its customers include pharmaceutical and biotechnology companies, as well as academic and nonprofit research centers. n Complete Genomics proved that it could sequence a complete human genome with 99.999% accuracy as early as February 2009. n The company is currently sequencing 100 genomes (50 tumor-normal pairs) for a National Cancer Institute pediatric cancer study. n Current applications of its technology include the discovery of causal variants for rare diseases, research into perplexing clinical cases and the identification and validation of somatic mutations in cancer patients.
n Future applications include stratifying patients for clinical trials, cancer pathology and newborn screening. n Ultimately, having one's genome sequenced will become as routine as getting a blood test.
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